RegionInternational. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  Survodutide (BI 456906)
Research reference — not for sale

Survodutide (BI 456906)

B
lead outcome
Weight loss (obesity, no diabetes)
grades vary by outcome ↓
Peptide
also called — Survodutide · development code BI 456906
metabolicweight lossMASH / hepatic fat (the differentiator)glycaemic

The glucagon arm of the incretin map — and the register's clearest "different second receptor, different job" story. Three points make this entry pop: (1) it's a GLP-1 / glucagon dual agonist — the glucagon half is what sets it apart from tirzepatide (#2, GLP-1/GIP), giving it a unique liver-fat-burning mechanism; (2) Phase 3 just read out (April 2026): −16.6% body weight at 76 weeks — real late-stage data, not hype; (3) it is being built as much for MASH (fatty-liver disease) as for obesity — a genuinely differentiated positioning in a crowded field.

In brief

Survodutide is an investigational GLP-1 / glucagon dual-agonist peptide (weekly injection) from Boehringer Ingelheim and Zealand Pharma. What makes it distinct is the second receptor: instead of tirzepatide's GIP, survodutide adds glucagon-receptor activation, which raises energy expenditure (the liver burns more calories — a thermogenic effect GIP doesn't provide) and directly drives hepatic fat oxidation. That's why its MASH (fatty-liver) data are among the most striking in the field (Phase 2 MASH resolution ~83% at top dose), and why it's being developed as much for liver disease as for obesity. On weight, its Phase 3 SYNCHRONIZE-1 delivered −16.6% at 76 weeks — clinically meaningful, though numerically below tirzepatide's ~20.9% (no head-to-head trial exists). The glucagon arm is a double-edged sword: it adds fat-burning but, without GIP's insulin-releasing "safety net," and given glucagon's historic tendency to raise blood sugar, it demands careful GLP-1-balanced titration and carries transient liver-enzyme and heart-rate signals.

Legal standing, by region
European Union
Not approved

not approved anywhere (Phase 3, investigational). No EMA/FDA marketing authorisation; not a cosmetic; no compounding pathway.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Weight loss (obesity, no diabetes)
Strong, positive Phase 3 — but not yet approved (confirmatory/regulatory pending); below tirzepatide numerically (no direct comparison)
Phase 3 SYNCHRONIZE-1 (2026): −16.6% at 76 wk vs 3.2% placebo, p<0.0001; 85.1% ≥5% loss. Phase 2 (2024): −14.9% at 46 wk
B
MASH resolution / hepatic fat
Standout Phase 2 liver data (the glucagon-arm advantage); Phase 3 MASH histology outcomes still to confirm
Phase 2 MASH (Sanyal, NEJM 2024): resolution ~83% top dose vs ~18% placebo; dedicated Phase 3 LIVERAGE ongoing
B
Glycaemic control (T2D)
In development; glucagon component makes glucose handling a balance rather than a pure win
SYNCHRONIZE-2 (obesity + diabetes) in Phase 3
C
Cardiovascular outcomes
Being formally tested; no outcome data yet; transient heart-rate increase is a class + glucagon consideration
SYNCHRONIZE-CVOT ongoing
Safety / tolerability
GI effects (nausea/diarrhea/vomiting — GLP-1 class); transient aminotransferase (liver-enzyme) elevations; small transient heart-rate rise (glucagon-mediated sympathetic activation); the missing-GIP "insulin safety net" makes titration more demanding
Phase 2/3 program
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Survodutide (BI 456906) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Identity

an investigational peptide engineered for weekly subcutaneous dosing via a fatty-acid albumin-binding strategy (the same long-acting trick as semaglutide and tirzepatide). Developed by Boehringer Ingelheim in partnership with Zealand Pharma. Its defining feature is which two receptors it hits: GLP-1 and glucagon — deliberately not GIP.

Mechanism (as proposed)

survodutide co-activates two receptors. The GLP-1 arm does the familiar work: suppresses appetite, slows gastric emptying, improves glycaemia. The glucagon (GCGR) arm is the differentiator: although glucagon is classically a counter-regulatory hormone that raises blood sugar, deliberately activating its receptor increases hepatic energy expenditure (the liver burns more calories processing nutrients — a thermogenic effect) and directly promotes liver fat oxidation (breaking down stored hepatic fat). The GLP-1 component is needed partly to offset glucagon's glucose-raising tendency. This is why survodutide targets the fat accumulation that defines MASH more directly than pure incretin drugs — but also why its safety requires balancing two opposing glucose effects.

Sources — 5 cited
01Boehringer Ingelheim / Zealand Pharma — SYNCHRONIZE-1 Phase 3 topline (April 2026) and ADA-2026 presentation; published in NEJM (SYNCHRONIZE-1) and Nature Medicine (SYNCHRONIZE-MASLD).
02le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: dose-finding Phase 2 trial. Lancet Diab Endocrinol. 2024;12:162–173.
03Sanyal AJ, et al. A Phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311–319.
04Zimmermann T, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist. Mol Metab. 2022;66:101633.
05Trial registrations: NCT06066515 (SYNCHRONIZE-1), NCT06066528 (SYNCHRONIZE-2); LIVERAGE (MASH).
Updated 2026-07-13 (fast-moving — additional SYNCHRONIZE and LIVERAGE read-outs expected through 2026; re-check obesity + MASH Phase 3 completeness and any regulatory filing)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
TirzepatideA
Peptide
RetatrutideB
Peptide
SemaglutideA
Peptide
Mazdutide (IBI362 / LY3305677)A
Peptide
AmycretinB
Peptide
Explore by goal
Metabolic
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

RegionInternational
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen dataBrands
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.